Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Full-text index only
Increased risk of breast cancer among female relatives of patients with ataxia-telangiectasia: a causal relationship?
PMID 16222317 · PMC2361617 · British journal of cancer · 2005 · 6 claims · 3 setups
Breast cancer risk is strongly and significantly elevated specifically among mothers of AT patients (SIR=7.14), consistent with Olsen et al's finding (SIR=6.7)
-
Full-text index only
Getting knit-PI3Ky: PIK3CA mutation status to direct multimodality therapy?
PMID 19903790 · PMC3400141 · Clinical cancer research : an official journal of the American Association for Cancer Research · 2009 · 8 claims · 1 setups
PIK3CA mutations are associated with local disease recurrence in rectal cancer patients
-
Full-text index only
Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients.
PMID 17626639 · PMC1952070 · BMC cancer · 2007 · 7 claims · 4 setups
EGFR mutations (exon 19 deletions, exon 21 L858R) did not correlate with gefitinib response in this cohort
-
Full-text index only
Bioinformatics methods for learning radiation-induced lung inflammation from heterogeneous retrospective and prospective data.
PMID 19704920 · PMC2688763 · Journal of biomedicine & biotechnology · 2009 · 8 claims · 3 setups
Kernel-based methods (e.g., SVM) can capture nonlinear dose-volume interactions relevant to predicting radiation pneumonitis
-
Full-text index only
25th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, 10-14 December 2002 Update on preclinical and translational research.
PMID 12631391 · PMC154153 · Breast cancer research : BCR · 2003 · 8 claims · 8 setups
Growth factor signalling (EGF/HER-2/MAPK, AKT) phosphorylates the oestrogen receptor and drives development of endocrine-resistant breast cancer
-
Full-text index only
Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk.
PMID 10027313 · PMC2362434 · British journal of cancer · 1999 · 7 claims · 5 setups
Allelic distribution of the Cyp19 intron 4 STRP differs significantly between breast cancer cases and controls
-
Full-text index only
Future possibilities in the prevention of breast cancer: intervention strategies in BRCA1 and BRCA2 mutation carriers.
PMID 11250722 · PMC138789 · Breast cancer research : BCR · 2000 · 8 claims · 8 setups
BRCA1 and BRCA2 mutations confer an 80-85% lifetime risk (by age 80) of female breast cancer
-
Full-text index only
Prevalence of BRCA1 in a hospital-based population of Dutch breast cancer patients.
PMID 10952774 · PMC2363536 · British journal of cancer · 2000 · 8 claims · 5 setups
The estimated prevalence of BRCA1 mutations in the general Dutch breast cancer population is 2.1%
-
Full-text index only
Expression genomics in breast cancer research: microarrays at the crossroads of biology and medicine.
PMID 17397520 · PMC1868923 · Breast cancer research : BCR · 2007 · 8 claims · 8 setups
Genome-wide expression microarray studies reveal transcriptional networks/signatures that explain breast cancer biological and clinical heterogeneity
-
Has reproduction · 75
PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy.
PMID 33188038 · PMC7668369 · Journal for immunotherapy of cancer · 2020 · 7 claims · 6 setups
The frequency of circulating PD-1+TIGIT+ (DPOS) CD8+ T cells after 1 month of anti-PD-1 therapy is associated with clinical response and overall survival
-
Has reproduction · 64
Spatial-reprogramming derived GPNMB(+) macrophages interact with COL6A3(+) fibroblasts to enhance vascular fibrosis in glioblastoma.
PMID 41174767 · PMC12577258 · Genome medicine · 2025 · 8 claims · 8 setups
COL6A3+ TAFs are a distinct matrix-fibroblast subset significantly enriched in non-responders to neoadjuvant antiangiogenic+ICB combination therapy